# A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects

> **NCT06684041** · PHASE1 · COMPLETED · sponsor: **Chengdu Suncadia Medicine Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Hemolytic Anemia

## Interventions

- **DRUG:** HRS-5965 capsule
- **DRUG:** HRS-5965 capsule placebo

## Key facts

- **NCT ID:** NCT06684041
- **Lead sponsor:** Chengdu Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-09
- **Primary completion:** 2025-04-07
- **Final completion:** 2025-04-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06684041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06684041, "A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06684041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*